Docetaxel and oxaliplatin combination in second-line treatment of patients with advanced gastric cancer

A phase II study of doxifluridine and docetaxel combination chemotherapy for advanced or recurrent gastric cancer

“…Several investigators have reported on the efficacy of second-line chemotherapy for gastric cancer using various combinations of docetaxel with another anticancer agent. Response rates in these combinations ranged from 10.5% to 29% [23][24][25][26][27][28]. Thus, our result was equivalent to those in most of these studies.…”

“…In the Japanese Clinical Oncology Group (JCOG) 9912 trial, the median overall survival time was 10.8 months with 5-FU, 12.3 months with CPT-11 and cisplatin, and 11.4 months with S1 [20]. In several previous reports of second-line chemotherapy, the median overall survival time ranged from 4 to 9 months [25][26][27][28]. In contrast to the overall survival time in the present study, the median progression-free survival was unimpressive, at 2.6 months, meaning that the patients generally lived long after disease progression.…”

Second-line chemotherapy for gastric cancer: a new issue lies ahead in global trials

“…However, the effects of monotherapy are limited [20][21][22][23][24][25]. Various combination therapies have been investigated in small-scale, phase II studies [26][27][28][29][30][31][32][33]. However, according to the results of some recent studies, the response rates ranged from approximately 10 to 20%, and PFS ranged from 2.5 to 4.0 months.…”

“…Most recently reported studies of second-line chemotherapy consist of small-scale phase II or retrospective trials [19][20][21][22][23][24][25][26][27][28][29][30][31][32][33]. No randomized control trial to establish standard treatment has been conducted.…”

A multiple-center phase II study of weekly docetaxel and oxaliplatin as first-line treatment in patients with advanced gastric cancer

“…These agents have distinct and complementary mechanisms of action, potential lack of cross-resistance, and different toxicity and favorability profiles. To date, several phase II trials have been conducted to assess the potential of triweekly docetaxel-oxaliplatin (DO) combinations in advanced gastric cancer [15][16][17]. The US Oncology Group study (n = 71) showed an overall response rate of 47% with first-line D 60 mg/m 2 on day 1 plus OXA 130 mg/m 2 on day 1 every 3 weeks until progression, but with a significant incidence of hematological toxicity (68% grade 3/4 neutropenia and 6% febrile neutropenia) [15].…”